RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
March 31, 2021
RegMed Investors’ (RMi) pre-open: a mixed bag, strength is a mixed bag to sell into
March 30, 2021
RegMed Investors’ (RMi) closing bell: market dumps, sector jumps
March 29, 2021
RegMed Investors’ (RMi) closing bell: flipping the bird to risk
March 29, 2021
RegMed Investors’ (RMi) pre-open: deal after reshuffling the deck with two (2) sessions left in month and quarter
March 26, 2021
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector strength migrated to weakness
March 26, 2021
RegMed Investors’ (RMi) pre-open: TGIF, strength is migratory and the cell and gene therapy sector seems directionless
March 25, 2021
RegMed Investors’ (RMi) closing bell: the zig and the zag, from weakness to strength in four (4) hours
March 24, 2021
RegMed Investors’ (RMi) closing bell: we are suffering from a lack of appetite for cell and gene therapy companies
March 22, 2021
RegMed Investors’ (RMi) closing bell: through the prism of an upside markets, some cell and gene therapy equities take a mulligan
March 18, 2021
RegMed Investors’ (RMi) closing bell: falling knives draw equity blood
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.